RPRXRoyalty Pharma plc
Price
+59%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, no red flags, price roughly fair, growth steady, the market undecided.
We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
In the company’s own words · 10-K filed Feb 11, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Royalty Pharma plc (RPRX) reported revenue of $674M in Q2 2026 (quarter ended Jun 30, 2026), up 16% from the same quarter a year earlier. That came with net income of $18M (2.7% of revenue). For the full year FY2025, revenue was $2.38B (+5.1% year on year) and net income $771M. Its largest product in Q2 2026 was Financial Royalty Assets at $638M, 95% of the disclosed total, well ahead of Royalty Income Other at 5.4%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- May 28, 2026On May 22, 2026, Royalty Pharma plc (the “Company”), Royalty Pharma Holdings Ltd, a non-wholly owned consolidated subsidiary of the Company (“RPH”), and Royalty Pharma Manager, LLC (“RPM”) entered into that certain Revolving Credit Agreement with Bank of America, N.A., as Administrative Agent (the “Administrative …Material agreement entered · Form 8-K
- Dec 22, 2025On December 20, 2025, George W. Lloyd, age 66, informed Royalty Pharma plc (the “Company”) of his decision to transition from his role of Executive Vice President and Chief Legal Officer effective December 31, 2025.Director or officer change · Form 8-K
- Sep 16, 2025On September 16, 2025, Royalty Pharma plc (the “Issuer”) closed its previously announced offering (the “Offering”) of $600 million aggregate principal amount of 4.450% Senior Notes due 2031 (the “2031 Notes”), $900 million aggregate principal amount of 5.200% Senior Notes due 2035 (the “2035 Notes”) and $500 million …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $674.1MThe company’s own SEC segment disclosure.
- Financial Royalty Assets$638.0M95%
- Royalty Income Other$36.1M5%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.